In vitro fibrin clot formation and fibrinolysis using heterozygous plasma fibrinogen from γAsn319, Asp320 deletion dysfibrinogen, Otsu I

Thrombosis Research

Volumn 118, Issue 5, 2006, Pages 651-661

  Terasawa, Fumiko ^a   Kani, Satomi ^b   Hongo, Minoru ^a   Okumura, Nobuo ^a  

^a SHINSHU UNIVERSITY   (Japan)

^b NAGOYA CITY UNIVERSITY HOSPITAL   (Japan)

Author keywords

319; 320 deletion; Dysfibrinogen; Fibrin clot formation; Fibrinolysis; Tissue type plasminogen activator

Indexed keywords

FIBRIN; FIBRINOGEN; FIBRINOGEN OTSU 1; PLASMIN; PLASMINOGEN; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOT LYSIS; DYSFIBRINOGENEMIA; ENZYME ACTIVATION; FIBRIN CLOT; FIBRIN POLYMERIZATION; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; GENE DELETION; PRIORITY JOURNAL; PROTEIN DEGRADATION; SCANNING ELECTRON MICROSCOPY;

AFIBRINOGENEMIA; BLOOD COAGULATION; CODON, NONSENSE; FIBRINOGENS, ABNORMAL; FIBRINOLYSIS; GENE DELETION; HUMANS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33748775473     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2005.10.013     Document Type: Article

References (31)

1. Olexa S.A., and Budzynski A.Z. Evidence for four different polymerization sites involved in human fibrin formation. Proc Natl Acad Sci U S A 77 (1980) 1374-1378
2. http://www.geht.org/pages/databaseang/fibrinogen/.
3. Koopman J., Haverkate F., Briet E., and Lord S.T. A congenitally abnormal fibrinogen (Vlissingen) with a 6-base deletion in the γ-chain gene, causing defective calcium binding and impaired fibrin polymerization. J Biol Chem 266 (1991) 13456-13461
4. Haverkate S., and Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC subcommittee on fibrinogen. Thromb Haemost 73 (1995) 151-161
5. Hogan K.A., Gorkun O.V., Lounes K.C., Coates A.I., Weisel J.W., Hantgan R.R., et al. Recombinant fibrinogen Vlissingen/Frankfurt IV. J Biol Chem 275 (2000) 17778-17785
6. Okumura N., Gorkun O.V., and Lord S.T. Severely impaired polymerization of recombinant fibrinogen γ-364 Asp→His, the substitution discovered in a heterozygous individual. J Biol Chem 272 (1997) 29596-29601
7. Terasawa F., Hogan K.A., Kani S., Hirose M., Eguchi Y., Noda Y., et al. Fibrinogen Otsu I: A γAsn319, Asp320 deletion dysfibrinogen identified in an asymptomatic pregnant woman. Thromb Haemost 90 (2003) 757-758
8. Hirota-Kawadobora M., Terasawa F., Yonekawa O., Sahara N., Shimizu E., Okumura N., et al. Fibrinogen Kosai and Ogasa: Bβ15Gly→Cys (GGT→TGT) substitution associated with impairment of fibrinopeptide B release and lateral aggregation. J Thromb Haemost 1 (2003) 275-283
9. Ishikawa S., Hirota-Kawadobora M., Tozuka M., Ishii K., Terasawa F., and Okumura N. Recombinant fibrinogen, γ275Arg→Cys exhibits formation of disulfide bond with cysteine and severely impaired D:D interactions. J Thromb Haemost 2 (2003) 468-475
10. Wilhelm S.E., Lounes K.C., and Lord S.T. Investigation of residues in the fibrin(ogen) γ chain involved in tissue plasminogen activator binding and plasminogen activation. Blood Coagul Fibrinolysis 15 (2004) 451-461
11. Meh D.A., Mosesson M.W., DiOrio J.P., Siebenlist K.R., Hernandez I., Amrani D.L., et al. Disintegration and reorganization of fibrin networks during tissue-type plasminogen activator-induced clot lysis. Blood Coagul Fibrinolysis 12 (2001) 637-672
12. Mullin J.L., Norfolk S.E., Weisel J.W., and Lord S.T. Clot lysis of variant recombinant fibrinogens confirms that fiber diameter is a major determinant of lysis rate. Ann NY Acad Sci 936 (2001) 331-334
13. Terasawa F., Okumura N., Kitano K., Hayashida N., Shimosaka M., and Okazaki M. Hypofibrinogenemia associates with a heterozygous missense mutation γ153Cys to Arg (Matsumoto IV): in vitro expression demonstrates defective secretion of the variant fibrinogen. Blood 94 (1999) 4122-4131
14. Terasawa F., Fujita K., and Okumura N. Residue γ153Cys is essential for the formation of the complexes Aαγ and Bβγ, assembly intermediates for the AαBβγ complex and intact fibrinogen. Clin Chim Acta 353 (2005) 157-164
15. Glanakis D.K., Spitzer S.G., Scharrer I., and Peerschke E.I. Impaired platelet aggregation support by two dysfibrinogens: a γ319-320 deletion and a γ310Met→Thr substitution. Thromb Haemost 69 (1993) 2564
16. Kluft C. The fibrinolytic system and thrombotic tendency. Pathophysiol Haemost Thromb 33 (2003/4) 425-429
17. Yee V.C., Pratt K.P., Côté H.C.P., Le Trong I., Chung D.W., Davie E.W., et al. Crystal structure of a 30 kDa C-terminal fragment from the γ chain of human fibrinogen. Structure 5 (1997) 125-138
18. Yakovlev S., Makogonenko E., Kurochkina N., Nieuwenhuizen W., Ingham K., and Medved L. Conversion of fibrinogen to fibrin: mechanism of exposure of tPA- and plasminogen-binding sites. Biochemistry 39 (2000) 15730-15741
19. Yonekawa O., Voskuilen M., and Nieuwenhuizen W. Localization in the fibrinogen γ-chain of a new site that is involved in the acceleration of the tissue-type plasminogen activator-catalyzed activation of plasminogen. Biochem J 283 (1992) 187-191
20. Hogan K.A., Merenbloom B.K., Kim H.S., and Lord S.T. Neonatal bleeding and decreased plasma fibrinogen levels in mice modeled after the dysfibrinogen Vlissingen/Frankfult IV. J Thromb Haemost 2 (2004) 1484-1487
21. Soria J., Soria C., and Caen J.-P. A new type of congenital dysfibrinogenaemia with defective fibrin lysis - Dusard syndrome: possible relation to thrombosis. Br J Haematol 53 (1983) 575-586
22. Lijnen H.R., Soria J., Soria C., Collen D., and Caen J.-P. Dysfibrinogenemia (fibrinogen Dusard) associated with impaired fibrin-enhanced plasminogen activation. Thromb Haemost 51 (1984) 108-109
23. Koopman J., Haverkate F., Grimbergen J., Lord S.T., Mosesson M.W., DiOrio J.P., et al. Molecular basis for fibrinogen Dusart (Aα554Arg→Cys) and its association with abnormal fibrin polymerization and thrombophilia. J Clin Invest 91 (1993) 1637-1643
24. Collet J.-P., Soria J., Mirshahi M., et al. Dusart syndrome: a new concept of the relationship between fibrin clot architecture and fibrin clot degradability: hypofibrinolysis related to an abnormal clot structure. Blood 82 (1993) 2462-2469
25. Collet J.-P., Woodhead J.L., Soria J., et al. Fibrinogen Dusart: electron microscopy of molecules, fibers and clots, and viscoelastic properties of clots. Biophys J 70 (1996) 500-510
26. Mosesson M.W., Siebenlist K.R., Hainfeld J.F., Wall J.S., Soria C., and Caen J.P. The relationship between the fibrinogen D domain self-association/cross-linking site (γXL) and the fibrinogen Dusart abnormality (AαR554C-albumin). Clues to thrombophilia in the "Dusart syndrome". J Clin Invest 97 (1996) 2342-2350
27. Koopman J., Harverkate F., Lord S.T., Grimbergen J., and Mannucci P.M. Molecular basis of Naples associated with defective thrombin binding and thrombophilia. Homozygous substitution of Bβ68Ala→Thr. J Clin Invest 90 (1992) 238-244
28. Meh D.A., Mosesson M.W., et al. Fibrinogen Naples I (Bβ A68T) nonsubstrate thrombin-binding capacities. Thromb Res 103 (2001) 63-73
29. Koopman J., Harverkate F., and Grimbergen J. Abnormal fibrinogens Ijmuiden (BβArg14→Cys) and Nijmegen (BβArg44→Cys) form disulfide-linked fibrinogen-albumin complexes. Proc Natl Acad Sci 89 (1992) 3478-3482
30. Engesse L., Koopman J., and de Munk G. Fibrinogen Nijmegen: congenital dysfibrinogenemia associated with impaired t-PA mediated plasminogen activation and decreased binding of t-PA. Thromb Haemost 60 (1988) 113-120
31. Mosesson M.W. Dysfibrinogenemia and thrombosis. Sem Thrmb Hemost 25 (1999) 311-319